Form 4: Tandem Diabetes Care COO Boosts Shareholding Through RSU Vesting

Tandem Diabetes Care's EVP & Chief Operating Officer, Jean-Claude Kyrillos, acquired 14,545 shares of common stock through the vesting of restricted stock units, with a portion withheld for tax obligations.

Summary

• Jean-Claude Kyrillos, EVP & Chief Operating Officer of Tandem Diabetes Care Inc. (TNDM), acquired 14,545 shares of common stock on July 15, 2025, through the vesting of restricted stock units (RSUs).
• These RSUs were initially awarded on July 15, 2024, under the company's 2023 Long-Term Incentive Plan.
• A total of 5,205 shares were withheld by Tandem Diabetes Care, Inc. at a price of $15.2 per share to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, Kyrillos beneficially owns 20,049 shares of common stock and 29,089 derivative restricted stock units.
• The RSUs vest 33% on July 15, 2025, with the remaining shares scheduled to vest in eight equal quarterly installments thereafter.

Sentiment

Score: 7

Explanation: The transaction reflects a routine executive compensation event (RSU vesting), which increases the executive's direct ownership in the company, generally viewed positively as it aligns executive interests with shareholders. The tax withholding is a standard part of such transactions.

Positives

• EVP & COO Jean-Claude Kyrillos acquired 14,545 shares of common stock, increasing his direct ownership in the company.
• The acquisition is a result of RSU vesting, indicating the fulfillment of long-term incentive plan conditions and aligning executive interests with shareholders.

Negatives

• 5,205 shares were withheld by the company to satisfy tax obligations, which reduced the net shares received by the executive.

Future Outlook

The remaining shares of the Restricted Stock Units are scheduled to vest in eight equal quarterly installments following July 15, 2025.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, which is specific to the individual and the company, and does not provide broader industry context.

Stakeholder Impact

• Shareholders: Increased alignment of the executive's interests with shareholders due to increased direct stock ownership.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• The remaining Restricted Stock Units (RSUs) will vest in eight equal quarterly installments following July 15, 2025.

Key Dates

Recommendation

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Jean-Claude Kyrillos, Stock Acquisition, Tax Withholding